Vanguard Global Advisers
TCRT icon

Vanguard Global Advisers’s Alaunos Therapeutics TCRT Stock Holding History

Vanguard Global Advisers’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.13K Hold
501
– – ﹤0.01% 3619
2026
Q1 		$1.43K Buy
+501
New +$1.5K ﹤0.01% 3628

Other funds holding TCRT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
AAP
Arax Advisory Partners Denver, Colorado $15.1B AUM 27.93% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Global Advisers's TCRT Position: Q2 2026 in Review

Vanguard Global Advisers held its Alaunos Therapeutics (TCRT) position steady in Q2 2026 at 501 shares worth $1.13K. The position accounts for ﹤0.01% of the portfolio, ranked #3619.

Vanguard Global Advisers first reported a position in TCRT in Q1 2026 and has held it in 2 quarters since. The position peaked at $1.43K in Q1 2026. 30 funds tracked by Wall St. Rank hold TCRT as of Q2 2026.

  • Vanguard Global Advisers held 501 shares of Alaunos Therapeutics worth $1.13K as of Q2 2026.
  • Vanguard Global Advisers left its Alaunos Therapeutics share count unchanged in Q2 2026.
  • Alaunos Therapeutics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #3619 holding.
  • Vanguard Global Advisers first reported a position in Alaunos Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Global Advisers's Alaunos Therapeutics position peaked at $1.43K in Q1 2026.
  • 30 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.